You searched for: comorbidity (Engelska - Maltesiska)

comorbidity
komorbidità

patients with adhd comorbidity
pazjenti b’komorbidità ta’ adhd

treatment options for comorbidity
għażliet ta’ trattament għal komorbidità

comorbidity — drug use and mental disorders
kondizzjoni sottovalutata

comorbidity is often underestimated and underdiagnosed.
il-ko-morbidità hija ħafna drabi sottostmata u sottodjanjostikata.

training treatment staff to deal with comorbidity research.
problemi ta’eżawriment huma komuni f’membri tal-persunal li jaħdmu ma’ persuni li jagħmlu użu middroga li jsofru minn ko-morbidità.

comorbidity – drug use and mental disorders:policy considerations
konklużjonijiet il-ko-morbidità – konsiderazzjonijiet ta’politika politika

we need to take account of comorbidity when treating drug users.’
marcel reimen, president il-bord ta’ l-amministrazzjoni ta’l-emcdda l-emcdda

table 1: mean improvement from baseline ymrs score by psychiatric comorbidity
tabella 1: titjib medju mil-linja bażi tal-punteġġ ymrs skont il-komorbidità psikjatrika

currently, treatment of comorbidity is often not effectively organised and lacks quality management.
fil-preżent, it-trattament tal-ko-morbidità ħafna drabi mhuwiex organizzat b’mod effettiv u jonqos fil-ġestjoni tal-kwalità.

for the treatment of problem drug users with comorbidity in prison, the authorities must also be involved.
għattrattament ta’ persuni bil-problema ta’ l-użu taddroga li jsofru minn komorbidità li qegħdin fil-ħabs, l-awtoritajiet għandhom ukoll jiġu involuti.

comorbidity is difficult to diagnose and both psychiatric teams and drug treatment services often fail to identify it in patients.
huwa diffiċli li l-ko-morbidità tiġi djanjostikata u kemm timijiet psikjatriċi kif ukoll servizzi għattrattament għad-droga ħafna drabi jonqsu li jidentifikawha fil-pazjenti.

consequently, many clients with comorbidity commence drug treatment without receiving treatment for their mental health problems.
b’konsegwenza, ħafna klijenti li jsofru minn komorbidità jibdew trattament għad-droga mingħajr ma jirċievu trattament għall-problemi tagħhom tas-saħħa mentali.

the incidence of intracranial bleeding was low in both treatment groups given the significant comorbidity and cv risk factors of the population under study.
l-inċidenza ta’ fsada ġol-kranju kienet baxxa fiż-żewġ gruppi ta’ kura minħabba l-fatturi ta’ komorbożità u ta’ riskju cv sinifikanti.

developing and adapting age-appropriate types of therapy, by including older people in clinical studies and comorbidity studies.
għandhom jiġu żviluppati u adattati forom ta’ terapiji skont l-età tal-pazjent, billi l-anzjani jiġu inklużi fl-istudji kliniċi u fl-istudji dwar il-komorbidità.

a multi-disciplinary comprehension of how to deal with patients with different patterns of comorbidity is vital for all levels of treatment staff.
komprensjoni multi-dixxiplinarja ta’ kif għandhom jiġu ttrattati pazjenti b’mudelli differenti ta’ komorbidità hija vitali fil-livelli kollha ta’personal għal trattament.

diagnosis and treatment of comorbidity is hampered by the fact that drug treatment staff generally know little about psychiatry, and psychiatric staff generally know little about drug treatment.
id-djanjożi u t-trattament għall-ko-morbidità huma ostakolati mill-fatt li persunal għattrattament taddroga ġeneralment ikun jaf ftit dwar il-psikjatrija, u persunal psikjatriku ġeneralment ikun jaf ftit dwar it-trattament għad-droga.

even when comorbidity is diagnosed, often it is not considered in subsequent drug treatment interventions or, in the case of psychiatric services, results in no drugrelated treatment.
anke meta l-ko-morbidità hija djanjostikata, ħafna drabi mhijiex ikkunsidrata f’interventi sussegwenti għattrattament taddroga jew, fil-każ ta’ servizzi psikjatriċi ma tirriżulta f’ebda trattament relatat mad-droga.

patients between 65 and 70 years of age were required to have at least one comorbidity that precluded the use of frontline chemo-immunotherapy with fludarabine, cyclophosphamide, and rituximab.
pazjenti li kellhom bejn 65 u 70 sena kien jeħtieġ li jkollhom mill-inqas komorbidità waħda li tipprekludi l-użu tal-aktar kimoimmunoterapija importanti bi fludarabine, cyclophosphamide, u rituximab.

patients with a history of delirium tremens, hallucinations, seizures, significant psychiatric comorbidity, or significant abnormalities of liver function as well as those with significant physical withdrawal symptoms at screening or randomisation were excluded.
pazjenti b’passat ta’ delirium tremens, alluċinazzjonijiet, aċċessjonijiet, mard sinifikanti psikjatriku ieħor jew anormalitajiet sinifikanti fil- funzjoni tal-fwied kif ukoll dawk b’sintomi fiżiċi sinifikanti ta’ nuqqas ta’ alkoħol waqt l-ewwel eżaminazzjoni jew waqt l-għażla b’mod arbitrarju ġew esklużi.